Table 2 Changes in glycemic control in patients between the two groups after therapy.

From: Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

Items

CSII

Metformin + CSII

P

24-hr MG

7.89 ± 1.62

6.62 ± 0.78

0.00

SD

1.92 ± 0.71

1.33 ± 0.51

0.00

CV

22.8 ± 6.2

18.6 ± 6.6

0.00

MAGE

4.62 ± 1.80

3.35 ± 1.71

0.00

AUC > 10

0.16 ± 0.16

0.04 ± 0.09

0.00

AUC < 3.9

0.01 ± 0.02

0.01 ± 0.03

0.71

0–6-hr MG

6.40 ± 1.54

5.97 ± 1.07

0.06

0–3-hr MG

6.40 ± 1.78

6.10 ± 1.37

0.26

3–6-hr MG

6.40 ± 1.45

5.84 ± 0.96

0.01

2-hr PBMG

9.16 ± 2.08

7.55 ± 1.62

0.00

2-hr PLMG

7.96 ± 1.71

6.88 ± 1.26

0.00

2-hr PDMG

8.28 ± 2.10

7.10 ± 1.33

0.00

  1. 24-hr MG: 24-hr mean glucose (mmol/L), SD: standard deviation (mmol/L), CV: coefficient of variation (%), MAGE: mean amplitude of glycemic excursions (mmol/L), AUC >10: the incremental area under curve of glucose >10.0 mmol/L (mmol/L*Day), AUC < 3.9: the incremental area under curve of plasma glucose < 3.9 mmol/L (mmol/L*Day), 0–6-hr MG: 0000–0600 o’clock mean glucose (mmol/L), 0–3-hr MG: 0000–0600 o’clock mean glucose (mmol/L), 3–6-hr MG: 0300–0600 o’clock mean glucose (mmol/L), 2-hr PBMG: 2-hr post breakfast mean glucose (mmol/L), 2-hr PLMG: 2-hr post lunch mean glucose (mmol/L), 2-hr PDMG: 2-hr post dinner mean glucose (mmol/L).
Back to article page